Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

Descriptions

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 1st July 2025.

VII.1.2) Text to be corrected in the original notice
Section number
IV.2.2.1

Instead of
Date
24 June 2025

Local time
12:00pm

Read
Date
1 July 2025

Local time
12:00pm

Section number
IV.2.7.1

Instead of
Date
24 June 2025

Local time
12:00pm

Read
Date
1 July 2025

Local time
12:00pm

Section number
II.1.4.1

Instead of
Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Read
Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 1st July 2025.

Section number
VI.3.0.1

Instead of
Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C41701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England

Read
Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12.00pm (noon) on Tuesday 1st July 2025.Atamis Project reference C341701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England